Qronto Inc. (QRON)

Overview

Qrons Inc. is a pioneering biotechnology firm rooted in the development of innovative products, therapies, and technologies designed to tackle various neuronal diseases. Initially established as BioLabMart Inc., the company underwent a significant rebranding to Qrons Inc. in August 2017, marking a new chapter in its commitment to addressing complex neurological conditions. With its foundation laid in 2016 and operating from Long Island City, New York, Qrons Inc. stands at the forefront of biotechnological advances, particularly in the domain of neural damage repair and treatment.

Products and Services

• QS100

QS100 emerges as a cutting-edge solution tailored for patients with penetrating brain injuries. This product represents a novel approach in the medical field, combining the versatility of 3D printing technology with the therapeutic potential of mesenchymal stem cells (MSCs). Embedded within a synthetic hydrogel, QS100 is designed as an injury-specific, implantable material that promises significant advancements in brain injury treatment.

• QS200

Building on the innovative foundation laid by QS100, QS200 introduces an injectable format of MSCs-synthetic hydrogel specifically formulated for the management of concussions and other diffused axonal injuries. This approach aims to provide a minimally invasive, yet highly effective treatment option for patients suffering from widespread neural damage, further exemplifying Qrons Inc.'s dedication to revolutionizing neuronal disease therapies.